At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
Mirikizumab - IV +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Healthy Chinese Subjects
In Brief
A Phase 1 clinical trial evaluating Mirikizumab - IV, Mirikizumab - SC, and 2 other interventions for Healthy. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug. It will last up to about 4 months for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartDec 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedOct 24, 2019
Enrollment StartDec 4, 2019
Primary CompletionDec 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.7 years ago
Interventions
Mirikizumab - IVdrug
Administered IV
Mirikizumab - SCdrug
Administered SC
Placebo - IVdrug
Administered IV
Placebo - SCdrug
Administered SC